Summary & Overview
HCPCS G6047: Dihydrotestosterone Laboratory Test
HCPCS Level II code G6047 represents testing for dihydrotestosterone (DHT), an androgen measured in clinical lab settings to evaluate hormonal conditions such as androgen excess or deficiency. As a laboratory test code, G6047 matters nationally for clinicians monitoring endocrine disorders, for laboratories billing payers, and for payers managing coverage of hormone assays. The code provides a standardized identifier for reimbursement and utilization tracking across outpatient and clinical laboratory settings.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns and benchmarks where available, typical sites of service and clinical context for ordering DHT testing, and a summary of associated billing considerations. The publication also outlines common modifiers and notes when data elements are not provided in the source input.
The content is designed to inform billing professionals, laboratory managers, and policy analysts about the clinical purpose of the test, where it is typically performed, and which major payers are relevant for claims submission. Data not available in the input is indicated explicitly where applicable.
Billing Code Overview
HCPCS Level II code G6047 describes Dihydrotestosterone, a laboratory analyte measured to assess androgen status. The service type is laboratory testing, and the typical site of service is clinical laboratory or outpatient laboratory collection. Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult assigned male at birth presenting to an endocrinology or urology clinic for evaluation and monitoring of androgen therapy. The clinical workflow begins with a consult documenting history of hypogonadism, androgen deficiency, androgen-responsive alopecia, or gender-affirming care. Baseline laboratory testing including serum testosterone, dihydrotestosterone (DHT), luteinizing hormone (LH), and liver function tests is performed. Medication selection includes topical, injectable, or oral formulations; G6047 identifies the Dihydrotestosterone product for administration or provision.
The patient returns for administration or pharmacy dispensing, with documentation of medication name, dosage, lot number, route, and patient consent. For administered doses, nursing documents vital signs, injection site, and any immediate adverse reactions. For laboratory monitoring, follow-up visits include reassessment of symptoms, DHT and testosterone levels, and adjustment of therapy. Typical settings include outpatient endocrinology clinics, urology offices, ambulatory infusion centers, and specialty pharmacies providing the drug or its technical component (TC).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
TC | Technical component | Use when billing only the technical component of a drug or service (e.g., pharmacy dispensing or facility preparation) separate from a professional component |